AngioDynamics, Inc.  

(Public, NASDAQ:ANGO)   Watch this stock  
Find more results for David A. Donnelly, Jr.�
14.31
0.00 (0.00%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 10.84 - 19.00
Open     -
Vol / Avg. 0.00/131,943.00
Mkt cap 507.18M
P/E 146.77
Div/yield     -
EPS 0.10
Shares 35.44M
Beta 0.73
Inst. own 91%
Oct 20, 2014
AngioDynamics Annual Shareholder Meeting (Estimated) Add to calendar
Oct 8, 2014
Q1 2015 AngioDynamics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 23, 2014
Q4 2014 AngioDynamics Inc Earnings Call - Webcast
Jul 23, 2014
Q4 2014 AngioDynamics Earnings Release
Jun 5, 2014
AngioDynamics at Jefferies Global Healthcare Conference
May 28, 2014
AngioDynamics at Craig-Hallum Institutional Investor Conference
May 19, 2014
AngioDynamics at UBS Global Healthcare Conference
May 14, 2014
AngioDynamics at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (May '14) 2014
Net profit margin -1.15% 0.87%
Operating margin 3.99% 3.79%
EBITD margin - 13.85%
Return on average assets -0.54% 0.39%
Return on average equity -0.80% 0.58%
Employees 1,330 -
CDP Score - -

Address

14 Plaza Drive
LATHAM, NY 12110
United States - Map
+1-518-7951400 (Phone)
+1-518-7951401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AngioDynamics, Inc. designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company�s segments include vascular segment and Oncology/Surgery. The Vascular segment, which is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets. The Oncology/Surgery segment, which is responsible for radio frequency (RF) and microwave ablation, embolization, NanoKnife and Habib product lines. On May 21, 2012, the Company acquired Navilyst Medical. In October 2012, the Company acquired Vortex Medical Inc. In February 2013, it acquired certain assets of Microsulis Medical Ltd.

Officers and directors

Howard W. Donnelly Independent Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Joseph M. DeVivo President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Mark T. Frost Chief Financial Officer, Executive Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
George W. Bourne Senior Vice President, Chief Technology & Operations Officer
Age: 53
Bio & Compensation  - Reuters
Matthew Kapusta Senior Vice President - Business Development
Age: 41
Bio & Compensation  - Reuters
Louis J. Mazzarese Senior Vice President, Chief Regulatory Officer
Age: 67
Bio & Compensation  - Reuters
John J. Soto Chief Commercial Officer, Interim Senior Vice President - Global Franchise, Peripheral Vascular
Age: 48
Bio & Compensation  - Reuters
Richard A. Stark Senior Vice President - Global Franchise, Oncology/Surgery
Age: 48
Bio & Compensation  - Reuters
Mark Stephens Senior Vice President - Administration
Age: 45
Bio & Compensation  - Reuters
Charles R. Greiner Vice President - Global Franchise, Vascular Access
Age: 46
Bio & Compensation  - Reuters